DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF MOOD DISORDERS, SLEEP DISORDERS, OR ATTENTION DEFICIT DISORDERS

摘要

Disclosed is the use of droxidopa, a synthetic amino acid precursor of norepinephrine, in the manufacture of a medicament for treating an attention deficit disorder. Also disclosed is a pharmaceutical composition comprising: - droxidopa, or a pharmaceutically acceptable ester, amide, salt, or solvate thereof, - a tricyclic antidepressant compound selected from the group consisting of amitriptyline, amoxapine, butriptyline, clomipramine, desipramine, dibenzepin, dosulepin, doxepin, imipramine, lofepramine, nortriptyline, protriptyline, trimipramine, and combinations thereof, and - a DOPA decarboxylase inhibiting compound.